Belgian drug discovery company Confo Therapeutics has secured 30 million euros ($33.6 million) in a Series A financing.
BioGeneration Ventures and Wellington Partners co-led the round with participation from new investors, Fund+ and Perceptive Advisors.
Moreso, existing investors, Capricorn Health-Tech Fund, Qbic, Participatie Maatschappij Vlaanderen NV, among others also joined the round.
Confo Therapeutics will use the net proceeds from the round to accelerate its drug discovery activities and to develop its pipeline of G-protein-coupled receptors modulating compounds to produce drug candidates for clinical trials.